Skip to content
Back to Compounds

Uridine monophosphate

Also called UMP, 5'-uridylic acid, uridine. Pyrimidine nucleotide (uridine precursor); grouped with cholinergic precursors.

At a glance3 outcomes graded

  • Memory, No effect foundEvidence maturity: Established
  • Mood, Early signalEvidence maturity: Mechanistic only
  • Sleep quality, No effect foundEvidence maturity: Mechanistic only
Safety notes
Evidence last reviewed Added to the site , updated 17 studies citedEditorial review: NootropicsWork Editorial TeamEducational, not medical advice

Safety notes

Sources report interactions with medicines.

Read safety and interactions

Bottom line

Uridine monophosphate (UMP) is a precursor of uridine, a nucleoside the brain uses to build membrane phospholipids [1][4]. The adult memory trials we found tested it inside a multinutrient drink in people with Alzheimer's disease, and a Cochrane review judged it probably makes little or no cognitive difference [8]. Diarrhea limited the highest oral doses tested [7].

Key takeaways

  • Uridine is a pyrimidine nucleoside involved in making RNA, glycogen and cell membranes, and UMP is a precursor that raises blood uridine when taken by mouth [3][4].
  • The controlled memory trials in adults we found all tested Souvenaid, a multinutrient drink containing UMP, in people with Alzheimer's disease, and a Cochrane review judged it probably makes little or no difference to cognitive function [8].
  • In healthy adults, studies so far are short and measure blood levels, brain chemistry or appetite rather than thinking skills [4][5][6].
  • Evidence for mood comes from one open-label case series of seven adolescents with bipolar disorder, and evidence for sleep comes from rodent studies [13][15].
  • Diarrhea was the dose-limiting side effect of high oral uridine doses in a dose-escalation study [7].

New to Uridine monophosphate? Start with What is uridine monophosphate? A plain-English guide.

Evidence by outcome

Memory

C, limited. No effect foundEvidence maturity: Established

7 studies linkedIndustry-funded
Why C, and history for Memory

Every controlled human memory trial found tested Souvenaid (Fortasyn Connect), a drink combining UMP with omega-3 fats, choline, B vitamins and other nutrients, in people with Alzheimer's disease, so no effect can be attributed to uridine and results may not apply to healthy adults. Two manufacturer-funded trials in mild disease reported memory gains, but a Cochrane review of three low-risk-of-bias trials judged that it probably makes little or no difference to cognitive function. A small pilot RCT in children using a DHA, vitamin D3 and uridine supplement could not show a cognitive effect; 14 of 16 children completed and its own power calculation called for 26. Animal work in gerbils supports the mechanism only. The best synthesis, a Cochrane review, found probably little or no difference in global or specific cognitive functions, so the direction is none (limited, mixed) rather than benefit.

Rubric condition met: C: results only in clinical populations being extrapolated to healthy adults; every memory RCT found used a multinutrient drink (UMP with omega-3s, choline, B vitamins and more) in people with Alzheimer's disease; no RCT of uridine alone in healthy adults

Grade history

  • : Graded C (awaiting approval)
  • : C to C (awaiting approval). The combination rule puts the multinutrient-drink context on the grade; direction changed from benefit to none because the Cochrane review of three low-risk-of-bias trials found probably little or no difference and the only healthy-population trial (children) could not show an effect but was underpowered by its own calculation (14 of 16 completed, 26 needed), so it adds little either way, while the positive memory results come from manufacturer-funded trials.
  • : C to C (awaiting approval). Maturity, bias summary and re-check date added
  • : C to C (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Memory

How sure are we? Memory

Evidence maturity: Established Established for the Souvenaid multinutrient drink in Alzheimer's disease (Cochrane review of 3 low-risk trials); for uridine itself, Mechanistic only.

Tested as: Uridine monophosphate inside the Souvenaid multinutrient drink

Who paid for the studies
All industry-funded
Risk of bias
Low. Every Souvenaid trial is manufacturer-linked (Nutricia).
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Material tested
Within a multinutrient drink (Souvenaid)
Rules applied
Population cap (logged, no further change): Alzheimer's disease; Combination only (logged, no further change): Multinutrient drink only; B2: one funder or group (logged, no further change): One manufacturer behind every trial
  • Could rise: Would move to C benefit for uridine alone with a preregistered RCT of uridine or UMP alone, of adequate size, positive on a memory primary outcome.
  • Could fall: Would move to N for the drink if a second Cochrane-quality synthesis restricted to low-risk trials were null.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Mood

D, preliminary. Early signalEvidence maturity: Mechanistic only

2 studies linkedShort-term onlySingle research group
Why D, and history for Mood

The only human mood data found is an uncontrolled case series of seven adolescents with bipolar disorder in which uridine was associated with lower symptom scores. With no placebo group, expectation and natural fluctuation cannot be excluded, and the population is clinical. A 7-day placebo-controlled brain spectroscopy study in 17 healthy men from an overlapping research group measured phospholipid precursors, not mood. With no controlled outcome data, the grade is D.

Rubric condition met: D: no controlled human outcome data; an uncontrolled case series counts as D. The only human mood data is one 6-week open-label case series, n = 7, in adolescents with bipolar disorder (a clinical population)

Grade history

  • : Graded C (awaiting approval)
  • : C to D (awaiting approval). Modifiers kept because the single 6-week series is short-term and from one group.
  • : D to D (awaiting approval). Maturity, bias summary and re-check date added
  • : D to D (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Mood

How sure are we? Mood

Evidence maturity: Mechanistic only The only human mood data is an uncontrolled, open-label case series of 7 adolescents; the human data are uncontrolled, which the method files under Mechanistic only.

Tested as: Uridine or uridine monophosphate

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
High. Uncontrolled case series.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
Grams a day
Rules applied
Uncontrolled data only (logged, no further change): Uncontrolled case series of 7
  • Could rise: Would move to C with any controlled trial, or an open-label trial with a prespecified outcome; to B only with two RCTs in a defined population.
  • Could fall: Would move to N only with adequately sized controlled trials that find no effect.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Sleep quality

D, preliminary. No effect foundEvidence maturity: Mechanistic only

1 study linked
Why D, and history for Sleep quality

Sleep-promoting effects come from brain-injection studies of synthetic N3-substituted uridine derivatives in mice and rats and receptor-binding work, summarized in a 2001 review that describes the uridine receptor as not yet characterized; the direction rests on these derivatives, not on oral uridine or UMP. No controlled trial of uridine on sleep in adults was found (PubMed and Europe PMC, November 11, 2026); the PubMed search also returned one infant cereal trial of a multi-ingredient product, which does not test uridine. Re-appraised November 14, 2026: the only support is a review of rodent work with synthetic N3-substituted uridine derivatives, partly by injection. Preclinical evidence cannot carry an effect direction.

Rubric condition met: D, no direction: animal and mechanistic evidence only; preclinical data cannot carry a direction

Grade history

  • : Graded D (awaiting approval)
  • : D to D (awaiting approval). Preclinical evidence cannot carry an effect direction.
  • : D to D (awaiting approval). Maturity, bias summary and re-check date added
  • : D to D (approved). Editor sign-off November 16, 2026: grade matches the editor-approved final page

Studies and full rationale for Sleep quality

How sure are we? Sleep quality

Evidence maturity: Mechanistic only Rodent brain-injection studies of synthetic N3-substituted uridine derivatives and receptor work only; preclinical evidence cannot carry an effect direction.

Tested as: Synthetic uridine derivatives (rodent studies)

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
Not assessed
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Matched
  • Could rise: Would move to C with any controlled human trial of oral uridine or UMP on sleep in adults.
  • Could fall: Not applicable at D; adequately sized null human RCTs would support N.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

Grades describe evidence for each outcome, not a recommendation. Open “Why” on a card for its rationale and dated grade history. How we grade

This page grades three outcomes: memory, mood and stress and sleep. Grades follow our published rubric (how we grade evidence), and the evidence matrix shows how uridine compares with other compounds graded the same way.

Does uridine improve memory?

The best synthesis we found is a 2020 Cochrane review of three randomized, placebo-controlled trials of Souvenaid in 1,097 people with Alzheimer's disease, a clinical population; results may not apply to healthy adults [8]. Souvenaid is a drink with a patented nutrient combination called Fortasyn Connect [8]; besides UMP it contains the omega-3 fats DHA and EPA, choline, vitamins B12, B6, C and E, folic acid, phospholipids and selenium [11]. Because of that mix, none of these trials can show what uridine does on its own.

The Cochrane authors rated the risk of bias of all three trials as low, and reported that one trial was funded by European grants and the other two by the manufacturer of Souvenaid [8]. Across prodromal (early, pre-dementia) Alzheimer's disease and mild to moderate dementia, they concluded that Souvenaid probably results in little or no difference in global or specific cognitive functions, with moderate-quality evidence [8]. In the prodromal trial, the rate of progression to dementia after 24 months showed little to no difference between Souvenaid and placebo [8].

Individual trials reported narrower memory findings. In Souvenir I, a 12-week randomized, double-blind trial in 225 drug-naive adults with mild Alzheimer's disease, funded by the manufacturer's Danone research center, delayed verbal recall improved compared with a control drink (P = .021), while the other outcome scales were unchanged [9]. In Souvenir II, a 24-week double-blind trial in drug-naive adults with mild Alzheimer's disease, which the Cochrane review lists as manufacturer-funded, a memory composite score rose more with the active drink than with the control (p = 0.023) [8][10]. The abstract's effect-size estimate has a confidence interval that crosses zero, so we do not quote it [10].

In LipiDiDiet, a 36-month double-blind trial in 311 adults with prodromal Alzheimer's disease who drank one 125 mL serving a day or a matched placebo, the composite cognitive score declined less with the active drink (between-group difference 0.212, 95% CI 0.044 to 0.380; P = 0.014), as did memory (P = 0.008) [11]. Danone Nutricia Research, the manufacturer, funded the trial from month 25 onward [11]. Only 81 of the 311 participants had 36-month data eligible for the efficacy analysis, which limits how much weight the long-term result can carry [11]. A 24-week trial in people with mild to moderate disease already taking Alzheimer's medication (S-Connect) observed no effects on cognition, according to the authors of a later extension study, one of whom is affiliated with Nutricia Research, the manufacturer [12].

The results are mixed. The positive findings come from memory measures and, in the 36-month trial, a cognitive composite score, all in early disease and in trials funded wholly or partly by the manufacturer. The Cochrane review found probably little or no difference in global or specific cognitive functions, and conflicting results on combined thinking-and-function scores [8][9][10][11].

Does uridine improve mood?

The only human mood data we found is a 6-week open-label case series of seven adolescents with bipolar disorder who were in a depressive episode, a clinical population; results may not apply to healthy adults [13]. Uridine was associated with decreased symptom scores and was well tolerated [13]. Open-label means everyone knew they were taking uridine and there was no comparison group, so expectation and natural change over time cannot be separated from any effect of uridine.

As of November 11, 2026 we found no placebo-controlled trials of uridine on mood in any population (PubMed and Europe PMC search, November 11, 2026). A related placebo-controlled study, with an author in common, gave 17 healthy men 2 g of uridine a day or placebo for seven days and found higher levels of phospholipid precursors on brain spectroscopy with uridine [5]. That is a brain-chemistry measure, not a mood outcome, and the uridine capsules were supplied by Repligen in an NIH-funded study [5].

Does uridine help sleep?

The sleep research we found is mainly in animals. A 2001 review summarizes work in which synthetic uridine derivatives injected into the brains of mice had hypnotic effects and one derivative promoted natural sleep in rats [15]. The authors propose that a "uridine receptor" in the brain may help trigger sleep, while noting that its structure has not been identified [15]. As of November 11, 2026 we found no controlled trials of uridine on sleep in adults (PubMed and Europe PMC search, November 11, 2026).

What the evidence does not show

As of November 11, 2026 we found no randomized trials of uridine or UMP taken alone that measured memory or other cognitive outcomes in healthy adults (PubMed and Europe PMC search, November 11, 2026). The closest test in healthy people is a 6-week randomized, placebo-controlled pilot trial in 16 children aged 8-11, which combined 1000 mg uridine with 500 mg DHA and 10 μg vitamin D3 [17]. It could not show a significant effect of the supplement on cognitive tests [17]. All children also did a cognitive and motor training program, 14 of 16 completed, and the authors calculated that 26 children would be needed [17].

Claims that uridine builds new synapses in people rest on animal studies. In gerbils fed UMP and choline and given DHA, maze performance improved more than with DHA and choline alone [14]. In one 7-day study in 17 healthy men, uridine raised some brain membrane precursor levels on spectroscopy [5], but no study we found links that change to better thinking in healthy adults.

One effect that has been measured in healthy adults is appetite. In two placebo-controlled, double-blind crossover studies in healthy young volunteers, single doses of 0.5 g or 1 g UMP raised blood uridine [4]. When levels stayed within the normal range, hunger and calorie intake rose in proportion to each person's baseline energy needs, while the higher, above-normal levels did not change intake behavior [4].

Doses used in studies

Ranges researchers used, not dosing advice. Bars share one scale. Read our disclaimer.

Single dose, healthy young adults (appetite studies)0.5 g or 1 g UMP once0.5 g
Healthy men, 7 days (brain spectroscopy)2 g uridine a day (1 g twice daily)2 g
Pharmacokinetic studies, healthy volunteersA supplement with about 6 g nucleosides per dose, mostly triacetyluridine; pure uridine at an equal molar dose6 g
Dose-escalation study, healthy volunteers and patients0.3-12 g/m2 single doses; 5-10 g/m2 every 6 hours for 3 days0.3 to 12 g
Multinutrient drink (Souvenaid) in Alzheimer's diseaseOne 125 mL drink daily for 12 weeks to 36 months

One 125 mL drink daily for 12 weeks to 36 months

Children aged 8-11, pilot trial1000 mg uridine with 500 mg DHA and 10 μg vitamin D3 daily for 6 weeks

1000 mg uridine with 500 mg DHA and 10 μg vitamin D3 daily for 6 weeks

Timing and form

Oral uridine is poorly absorbed. In a dose-escalation study in six healthy volunteers and nine patients with metastatic colorectal cancer (a clinical population), bioavailability of oral uridine ranged from 5.8% to 9.9% at the higher single doses [7]. In eight healthy volunteers (four men, four women), pure uridine produced a peak blood level of 36.1±11.3 µM 1-2 hours after dosing, and its half-life was 4.6±1.2 hours [6].

Form changes how much reaches the blood. In the same pharmacokinetic work, a supplement whose nucleosides were mostly triacetyluridine (TAU) produced peak concentrations and total exposure four times higher than an equal molar dose of pure uridine [6]. That study was NIH-funded, the supplement was supplied by PharmaNord, and one author consults for PharmaNord [6]. In the appetite studies, a single 1 g dose of UMP raised blood uridine to a peak at 2 hours that was about 4-fold higher than placebo and well outside the normal range [4].

The healthy-adult studies gave UMP as a single dose [4] or uridine twice a day [5], and the dose-escalation study also tested doses every 6 hours for 3 days [7]. None of the studies we used compared times of day.

What it is

Uridine is a pyrimidine nucleoside, which is one of the building blocks used by the body to produce RNA, glycogen, and cell membranes [3]. Much more uridine is found in human blood plasma than any other purine or pyrimidine nucleoside [3]. Uridine monophosphate (UMP) is used as a source of uridine in supplement studies as it increases the levels of uridine in the bloodstream when consumed orally [4]. UMP is found in Health Canada's ingredient database as 5'-uridylic acid by chemical name. The sub-ingredient of UMP is uridine and the CAS number is 58-97-9 [20].

Mechanism (how it might work): in the brain, uridine is converted to UTP and then CTP, which feed the Kennedy pathway (a chain of steps cells use to build membrane fats) that makes phosphatidylcholine and phosphatidylethanolamine, two membrane phospholipids [1]. A review of transport studies, much of it in rats, argues that uridine may reach the brain more readily than cytidine and may be the main pyrimidine source for this pathway [1]. Researchers in this field describe brain phosphatide synthesis as needing three circulating compounds: DHA (an omega-3 fat), uridine and choline [2]. Researchers in this field pair uridine with choline and DHA for this reason [2].

In experimental animals, giving these three precursors together increased brain phosphatides, synaptic proteins and the number of dendritic spines (the small contact points between nerve cells) [2]. The same review frames any benefit in people as conditional on similar increases occurring in the human brain [2]. Mechanism explains why uridine is studied; it does not show that a supplement changes memory, mood or sleep.

A related compound, uridine triacetate, is a medicine: FDA approved it in 2015 as an antidote for overdose and severe toxicity of the chemotherapy drugs fluorouracil and capecitabine [16]. Uridine itself is also used clinically as a rescue agent for the adverse effects of fluorouracil [3]. Those medical uses are outside the scope of this page, which covers uridine and UMP as supplement ingredients.

Safety and interactions

Safety flag. In a dose-escalation study, diarrhea was the dose-limiting effect of oral uridine; the maximum tolerated single dose was 10 to 12 g/m2 [7]. No adverse effects were reported in two 8-person pharmacokinetic studies of pure uridine and a triacetyluridine-rich supplement [6]. In multinutrient-drink trials in people with Alzheimer's disease, most funded wholly or partly by the manufacturer, adverse events were similar to the control drink, and a Cochrane review called adverse effects uncommon while noting long-term tolerability is not settled [8][11]. Single UMP doses that temporarily raised blood uridine within the normal range increased hunger and calorie intake in healthy young adults [4].

Who sources say should be careful.

As of November 11, 2026, the sources we checked (a PubMed safety search; we found no uridine page from the NIH Office of Dietary Supplements, the National Center for Complementary and Integrative Health or Memorial Sloan Kettering) do not name groups, such as people who are pregnant or breastfeeding or children, who should avoid uridine supplements. The human studies we used enrolled adults, apart from one pilot trial in children aged 8-11 and one case series in adolescents [13][17].

The sources describe a uridine prodrug used to counteract fluoropyrimidine chemotherapy medicines, such as fluorouracil or capecitabine [16]; see Interactions.

In the dose-escalation study, diarrhea was the dose-limiting side effect [7]. The maximum tolerated dose was 10 to 12 g/m2 as a single dose and 5 g/m2 when repeated every 6 hours [7].

At lower doses, short studies reported few problems. No adverse effects were reported with either pure uridine or the triacetyluridine-rich supplement in the pharmacokinetic studies [6]. In the 7-day study in healthy men, there were no adverse events apart from one fainting episode in the uridine group, which the authors could not clearly link to uridine [5]. In the adolescent case series, uridine was described as well tolerated [13].

The longest safety data come from the multinutrient-drink trials in people with Alzheimer's disease, a clinical population. In Souvenir II, a manufacturer-funded trial, serious and other adverse events did not differ between groups [8][10]. In a 24-week open-label extension with 201 participants, whose authors included one affiliated with Nutricia Research, pooled data showed 48 weeks of use was well tolerated with 96.1% intake adherence [12]. In LipiDiDiet, funded by the manufacturer from month 25, adverse and serious adverse events over 36 months were similar between groups [11]. The Cochrane review called adverse effects uncommon but said the evidence does not allow a definitive statement on long-term tolerability [8].

In healthy adults, single UMP doses that temporarily raised blood uridine within the normal range increased hunger and calorie intake in placebo-controlled studies [4]. These were single-dose studies, so they say nothing about longer-term effects on weight [4].

Interactions sources report

As of November 11, 2026 we found no studies of interactions between uridine supplements and medicines (PubMed search, November 11, 2026). The interaction in the sources concerns a prescription prodrug of uridine, uridine triacetate, which competes with the active metabolites of fluoropyrimidine chemotherapy drugs [16]. In early human studies it more than doubled the highest weekly fluorouracil dose people could tolerate, and it is used as the antidote for these medicines [16]. Uridine itself is used clinically as a rescue agent against the adverse effects of fluorouracil [3].

The medicines involved are fluoropyrimidine chemotherapy medicines, such as fluorouracil or capecitabine [16]. No source we found studied uridine supplements in people taking them.

If you take any of these medicines, talk to your doctor or pharmacist before combining them with uridine.

Products containing it

Partner product: we earn a commission

Qualia Night

Contains this compound among other ingredients. Our review compares each dose with the doses used in studies.

Read our review
Where to buy: partner product

Qualia Night contains Uridine monophosphate

Uridine monophosphate is one of 25 ingredient entries on the Qualia Night label. The grades on this page are for Uridine monophosphate on its own, not for the product.

Our Qualia Night review compares each label dose with the doses used in studies.

See Qualia Night at Qualia (affiliate link)

We earn a commission if you buy through this link. It never changes a grade or a verdict. How we make money.

FAQ

Is uridine monophosphate the same as uridine?

Not quite. Uridine monophosphate (UMP) is a uridine precursor: taken by mouth, it raised blood uridine in placebo-controlled studies in healthy adults [4]. Health Canada's ingredient database lists it under the chemical name 5'-uridylic acid, with uridine as its sub-ingredient [20].

Does uridine improve memory in healthy people?

As of November 11, 2026 we found no randomized trials of uridine or UMP taken alone that measured memory in healthy adults (PubMed and Europe PMC search, 2026-11-11). A 6-week pilot trial in 16 children, too small by its own power calculation, could not show any effect of a DHA, vitamin D3 and uridine supplement on cognitive tests [17]. Trials of a UMP-containing drink in people with Alzheimer's disease were judged to make probably little or no difference to cognitive function [8].

Why is uridine often paired with choline and omega-3 fats?

Researchers who developed the idea describe uridine, choline and DHA as the three circulating compounds the brain needs to make phosphatides (membrane phospholipids) [2]. In gerbils, adding UMP to DHA and choline further improved maze performance [14]. Whether the same happens in people is untested in healthy adults.

Can uridine affect appetite?

In two placebo-controlled crossover studies in healthy young adults, single UMP doses that kept blood uridine within the normal range increased hunger and calorie intake in proportion to each person's energy needs [4]. A 1 g dose that pushed levels well above the normal range did not change intake behavior [4].

References

  1. Cansev M. Uridine and cytidine in the brain: their transport and utilization. Brain Res Rev. 2006.PMID 16769123DOI 10.1016/j.brainresrev.2006.05.001Tier 1, narrative review
  2. Wurtman RJ, Cansev M, Sakamoto T, et al. Nutritional modifiers of aging brain function: use of uridine and other phosphatide precursors to increase formation of brain synapses. Nutr Rev. 2010.PMID 21091953DOI 10.1111/j.1753-4887.2010.00344.xTier 1, narrative review
  3. Yamamoto T, Koyama H, Kurajoh M, et al. Biochemistry of uridine in plasma. Clin Chim Acta. 2011.PMID 21689643DOI 10.1016/j.cca.2011.06.006Tier 1, narrative review
  4. Hanssen R, Rigoux L, Albus K, et al. Circulating uridine dynamically and adaptively regulates food intake in humans. Cell Rep Med. 2023.PMID 36652907DOI 10.1016/j.xcrm.2022.100897Tier 1
  5. Agarwal N, Sung YH, Jensen JE, et al. Short-term administration of uridine increases brain membrane phospholipid precursors in healthy adults: a 31-phosphorus magnetic resonance spectroscopy study at 4T. Bipolar Disord. 2010.PMID 21176029DOI 10.1111/j.1399-5618.2010.00884.xTier 1, controlled trial
  6. Weinberg ME, Roman MC, Jacob P, et al. Enhanced uridine bioavailability following administration of a triacetyluridine-rich nutritional supplement. PLoS One. 2011.PMID 21379380DOI 10.1371/journal.pone.0014709Tier 1, controlled trial
  7. van Groeningen CJ, Peters GJ, Nadal JC, et al. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst. 1991.PMID 1999851DOI 10.1093/jnci/83.6.437Tier 1
  8. Burckhardt M, Watzke S, Wienke A, et al. Souvenaid for Alzheimer's disease. Cochrane Database Syst Rev. 2020.PMID 33320335DOI 10.1002/14651858.CD011679.pub2Tier 1, systematic review
  9. Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement. 2010.PMID 20129316DOI 10.1016/j.jalz.2009.10.003Tier 1, RCT
  10. Scheltens P, Twisk JW, Blesa R, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012.PMID 22766770DOI 10.3233/JAD-2012-121189Tier 1, RCT
  11. Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimers Dement. 2021.PMID 32920957DOI 10.1002/alz.12172Tier 1, RCT
  12. Olde Rikkert MG, Verhey FR, Blesa R, et al. Tolerability and safety of Souvenaid in patients with mild Alzheimer's disease: results of multi-center, 24-week, open-label extension study. J Alzheimers Dis. 2015.PMID 25322923DOI 10.3233/JAD-141305Tier 1, RCT
  13. Kondo DG, Sung YH, Hellem TL, et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2011.PMID 21486171DOI 10.1089/cap.2010.0054Tier 1
  14. Holguin S, Martinez J, Chow C, et al. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J. 2008.PMID 18606862DOI 10.1096/fj.08-112425Tier 1
  15. Kimura T, Ho IK, Yamamoto I. Uridine receptor: discovery and its involvement in sleep mechanism. Sleep. 2001.PMID 11322706DOI 10.1093/sleep/24.3.251Tier 1, narrative review
  16. Thompson JT, Wood DM, Dargan PI. Review of the fluoropyrimidine antidote uridine triacetate. Br J Clin Pharmacol. 2025.PMID 39468799DOI 10.1111/bcp.16319Tier 1, narrative review
  17. Hansen SL, Ritterband-Rosenbaum A, Voigt CB, et al. Supplementation of docosahexaenoic acid (DHA), vitamin D3 and uridine in combination with six weeks of cognitive and motor training in prepubescent children: a pilot study. BMC Nutr. 2017.PMID 32153817DOI 10.1186/s40795-017-0155-1Tier 1
  18. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Updated August 27, 2026.SourceTier 1
  19. U.S. Food and Drug Administration. GRAS Notices inventory: search results for 'uridine'.SourceTier 1
  20. Health Canada (Natural and Non-prescription Health Products Directorate). Natural Health Products Ingredients Database: 5'-Uridylic acid (uridine monophosphate). Updated March 1, 2019.SourceTier 1
  21. Australian Government, Department of Health, Disability and Ageing (Federal Register of Legislation). Therapeutic Goods (Permissible Ingredients) Determination (No. 3) 2026 (F2026L01382), volumes 1 and 6. Updated October 13, 2026.SourceTier 1
Reviewed by NootropicsWork Editorial Team, editorial team. Checklist logged . Next review due . Report an error